Evidence map›Paper›PMID 30648824›Full record

ReviewInternational braz j urol : official journal of the Brazilian Society of Urology

Role of Adiponectin in prostate cancer.

Xiaobo Hu, Cong Hu, Caiping Zhang, Min Zhang, Shiyin Long, Zhaohui Cao

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Current mechanisms in obesity and tumor progression.Current opinion in clinical nutrition and metabolic care · 2020
    Review
  19. Article
  20. The Adipokines in Cancer Cachexia.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiaobo HuHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, China.
Cong HuDepartment of Biotechnology, School of Pharmacy and Biosciences, University of South China, Hengyang, China.
Caiping ZhangDepartment of Biotechnology, School of Pharmacy and Biosciences, University of South China, Hengyang, China.
Min ZhangDepartment of Biotechnology, School of Pharmacy and Biosciences, University of South China, Hengyang, China.
Shiyin LongDepartment of Biotechnology, School of Pharmacy and Biosciences, University of South China, Hengyang, China.
Zhaohui CaoHunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, China.
University of South China · CNCommunication University of China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity is defined as a chronic and excessive growth of adipose tissue. It has been associated with a high risk for development and progression of obesity-associated malignancies, while adipokines may mediate this association. Adiponectin is an adipose tissue-derived adipokines, with significant anti-diabetic, anti-inflammatory, anti-atherosclerotic and anti-proliferative properties. Plasma adiponectin levels are decreased in obese individuals, and this feature is closely correlated with development of several metabolic, immunological and neoplastic diseases. Recent studies have shown that prostate cancer patients have lower serum adiponectin levels and decreased expression of adiponectin receptors in tumor tissues, which suggests plasma adiponectin level is a risk factor for prostate cancer. Furthermore, exogenous adiponectin has exhibited therapeutic potential in animal models. In this review, we focus on the potential role of adiponectin and the underlying mechanism of adiponectin in the development and progression of prostate cancer. Exploring the signaling pathways linking adiponectin with tumorigenesis might provide a potential target for therapy.

Indexed as

AdiponectinAdipose TissueAnimalsDisease Models, AnimalDisease ProgressionHumansMaleObesityProstatic NeoplasmsReceptors, AdiponectinRisk FactorsAdiponectinReceptors, AdiponectinObesityProstatic NeoplasmsStress, Physiological

Identifiers

PMID30648824
PMCPMC6541146
OpenAlexW2945967593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.